Inflammatory Bowel Disease Drug Costs: Crohn's and Colitis

IBD Medication Costs: Understanding Your Options

Approximately 322,000 Canadians live with inflammatory bowel disease (IBD) — either Crohn's disease or ulcerative colitis. Canada has among the highest rates of IBD in the world. Treatment costs vary enormously depending on disease severity, from under $20 per month for mild cases to over $20,000 per year for patients requiring biologic therapy.

Common IBD Medications and Costs

First-Line and Maintenance Medications

Biologic and Advanced Therapies

Biosimilar Savings for IBD

Biosimilars have been transformative for IBD patients on biologic therapy. Biosimilar adalimumab (Hadlima, Hyrimoz) and biosimilar infliximab (Inflectra, Renflexis) have reduced costs by 40-50% compared to originator products. Several provinces now mandate biosimilar switching for both new and existing patients.

Provincial Coverage Highlights

• Ontario: ODB covers mesalamine, azathioprine, and other oral IBD medications. Biologics require Exceptional Access Program approval with documented treatment history.
• British Columbia: PharmaCare covers oral IBD medications and has an active biosimilar switching program. Special Authority is required for biologics.
• Alberta: The Alberta Drug Benefit covers standard IBD medications. Biologic coverage requires prior authorization through the Specialized High Cost Drug Program.
• Saskatchewan: The Saskatchewan Drug Plan covers oral IBD drugs and biologics with appropriate clinical criteria.

Patient Assistance Programs

• AbbVie Care provides patient support for Humira and guidance through biosimilar transitions.
• Janssen Patient Assistance supports Remicade and Stelara patients.
• Takeda Patient Support assists with Entyvio costs.
• Crohn's and Colitis Canada (crohnsandcolitis.ca) offers financial assistance, advocacy, and educational resources.
• GI Society (badgut.org) provides resources on managing IBD treatment costs.

Practical Tips for Managing IBD Drug Costs

Use generic 5-ASA and immunomodulators — Generic mesalamine, azathioprine, and methotrexate are significantly cheaper than brand-name versions.

Embrace biosimilars — If you are on Humira or Remicade, biosimilars are clinically equivalent and save thousands per year.

Enroll in manufacturer support — Biologic manufacturers offer copay assistance programs that can cover most or all of your out-of-pocket costs.

Compare pharmacy prices for oral medications — Use TransparentMedz to find the best prices on your daily IBD medications.

Apply for provincial drug programs — Most provinces cover biologics for IBD when clinical criteria are met.

Work with a GI specialist — Gastroenterologists are experienced with drug access programs and can advocate for coverage on your behalf.

Consider step therapy — Working up from less expensive medications to biologics only when needed is both clinically sound and cost-effective.

The Bottom Line

IBD medication costs range widely, but Canadian patients have strong coverage options. Generic oral medications keep mild-to-moderate disease affordable, while biosimilars have cut biologic costs nearly in half. Combine these with provincial programs, manufacturer assistance, and price comparison through TransparentMedz to manage the financial side of living with Crohn's disease or ulcerative colitis.